X4 Pharmaceuticals (XFOR) Projected to Announce Earnings on Wednesday

X4 Pharmaceuticals (NASDAQ:XFOR) is expected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.1820) per share and revenue of $2.30 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. The company had revenue of $8.81 million for the quarter, compared to analyst estimates of $2.42 million. On average, analysts expect X4 Pharmaceuticals to post ($0.67) EPS for the current fiscal year and ($0.73) EPS for the next fiscal year.

X4 Pharmaceuticals Stock Performance

Shares of XFOR opened at $3.25 on Wednesday. X4 Pharmaceuticals has a 52-week low of $2.43 and a 52-week high of $4.83. The company has a 50-day simple moving average of $3.37 and a 200-day simple moving average of $3.81.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, CFO David Kirske sold 11,767 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $2.86, for a total value of $33,653.62. Following the sale, the chief financial officer directly owned 155,983 shares in the company, valued at $446,111.38. The trade was a 7.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Adam R. Craig sold 47,436 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total transaction of $210,615.84. Following the completion of the sale, the chairman directly owned 328,651 shares in the company, valued at approximately $1,459,210.44. The trade was a 12.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 83,779 shares of company stock valued at $353,387. Insiders own 1.13% of the company’s stock.

Wall Street Analysts Forecast Growth

XFOR has been the topic of several recent analyst reports. Wells Fargo & Company started coverage on shares of X4 Pharmaceuticals in a research report on Friday, July 10th. They set an “overweight” rating and a $11.00 target price on the stock. Weiss Ratings downgraded shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 20th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $11.25.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.